Mycosis fungoides was so named by a French dermatologist in the 1800s due to the mushroom like tumors that developed on the skin of a patient with advanced disease. Mycosis fungoides typically ...

CTCL is characterized by the proliferation of ... histologically negative nodes IIB: skin tumors (regardless of percentage body surface area involved; nodes may or may not be clinically palpable ...

Denileukin diftitox is under clinical development by Citius Oncology and currently in Phase II for Solid Tumor.

German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell lymphoma (CTCL).

Mycosis fungoides is a type of skin cancer that affects the body's T cells, which are white blood cells intended to protect the body from infection. It is the most common form of cutaneous T-cell ...

CTCL is a class of non-Hodgkin’s lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which generally involve B-cell lymphocytes ...

Soligenix's FLASH2 Phase 3 trial for HyBryte in CTCL enrolls 80 patients, extending treatment to 18 continuous weeks for efficacy evaluation Interim results from the first Phase 3 showed a 49% ...